Compare Organon & Co. Common Stock (OGN) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.92 (market cap $2.51B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and SELLAS Life Sciences Group Inc. Common Stock for 0 Days on average.
| OGN | SLS | |
|---|---|---|
Market Cap | $3.62B | $2.51B |
Volume | 2,892,999 | 6,359,048 |
Sector | Health | Health |
52-Week High | $13.81 | $15.46 |
52-Week Low | $5.70 | $1.39 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $11.04B | $2.37B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SELLAS Life Sciences (SLS) trades at $12.41, up 4.02% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported no revenue in 2025, with a net loss of $26.86 million, negative ROE and ROA, and a high P/B ratio of 18.2. Recent news includes a law firm investigation into investor claims and positive preclinical data for SLS009 in pancreatic cancer models presented at the AACR conference.
The outlook hinges on upcoming clinical trial results, particularly the Phase 3 REGAL trial for GPS in AML, with topline data expected in Q4 2026. While analyst consensus is unanimously bullish, significant risks include the binary nature of trial outcomes, ongoing legal scrutiny, and persistent negative profitability metrics. The stock's recent surge of ~300% year-to-date reflects high investor optimism but also heightened volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
